Transfusion Medicine

  • James Gajewski
  • Susan Slater
Chapter

Abstract

The unique transfusion needs of a hematopoietic stem cell transplant (HSCT) patient require collaboration between the Clinical Transplant and Transfusion Medicine services. Successful interaction is essential to the optimal management of HSCT patients with the goals of reducing the risk of alloimmunization, infection transmission, and avoiding potential medical errors.

Keywords

Toxicity Dopamine DMSO Leukemia Hydrocortisone 

References

  1. Boeckh, M., Nichols, W., Papanicolaou, G., Rubin, R., Wingard, J., Zaia, J. (2003). Cytomegalovirus in hematopoietic stem cell transplants: Current status, known challenges, and future strategies. Bio Blood Marrow Transplant, 9:543–558.CrossRefGoogle Scholar
  2. Gajewski, J., Petz, L., Calhoun, L., et. al. (1992). Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. Blood, 79:3076–3085.Google Scholar
  3. Gajewski, J., Johnson, V., Sandler, G., Sayegh, A., Klumpp, T. (2008). A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood, 112:3036–3047.CrossRefPubMedGoogle Scholar
  4. Klumpp, T. (1991). Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant, 8:159–170.PubMedGoogle Scholar
  5. Lapierre, V., Mahé, C., Aupérin, A., et. al. (2005). Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplant, 80:314–319.Google Scholar
  6. LaRoche, V., Eastlund, D., McCullough, J. (2004). Review: Immunohematologic aspects of allogeneic hematopoietic progenitor cell transplantation. Immunohematology, 20:217–225.PubMedGoogle Scholar
  7. Nevo, S., Fuller, A., Zahurak, M., Hartley, E., Borinsky, M., Volgesang, G. (2007). Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 109 or 20 × 109/L. Transfusion, 49:1700–1709.Google Scholar
  8. Petz LD. (1987). Immunohematologic problems associated with bone marrow transplantation. Transfusion Med Rev, 1:85–100.Google Scholar
  9. Pihusch, M. (2004). Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol, 41(Supp 1):93–100.CrossRefPubMedGoogle Scholar
  10. Stroncek, D., McCullough, J. (1997). Policies and procedures for the establishment of an allogeneic blood stem cell collection program. Transfus Med, 7:77–87.CrossRefPubMedGoogle Scholar
  11. Worel, N., Grenix, H., Keil, F., et al. (2002). Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion, 42:1293–1301.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • James Gajewski
    • 1
  • Susan Slater
    • 1
  1. 1.Center for Hematologic Malignancies, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science UniversityPortlandUSA

Personalised recommendations